 Glucosides
"Glucosides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D005960
|
| MeSH Number(s) |
D09.408.348
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glucosides".
Below are MeSH descriptors whose meaning is more specific than "Glucosides".
This graph shows the total number of publications written about "Glucosides" by people in this website by year, and whether "Glucosides" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1986 | 1 | 0 | 1 | | 1993 | 1 | 1 | 2 | | 1994 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2013 | 2 | 0 | 2 | | 2014 | 2 | 1 | 3 | | 2015 | 0 | 1 | 1 | | 2017 | 1 | 0 | 1 | | 2018 | 1 | 2 | 3 | | 2019 | 1 | 0 | 1 | | 2020 | 1 | 2 | 3 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Glucosides" by people in Profiles.
-
Kohn OF. In CKD, the effect of dapagliflozin on kidney outcomes did not vary by T2DM status or CKD cause. Ann Intern Med. 2021 05; 174(5):JC53.
-
Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, Macaluso F, Sartori S, Roque M, Sabatel-Perez F, Rodriguez-Cordero A, Zafar MU, Fergus I, Atallah-Lajam F, Contreras JP, Varley C, Moreno PR, Abascal VM, Lala A, Tamler R, Sanz J, Fuster V, Badimon JJ. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2021 01 26; 77(3):243-255.
-
Kraus BJ, Weir MR, Bakris GL, Mattheus M, Cherney DZI, Sattar N, Heerspink HJL, Ritter I, von Eynatten M, Zinman B, Inzucchi SE, Wanner C, Koitka-Weber A. Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2021 03; 99(3):750-762.
-
Sternlicht HK, Bakris GL. Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes? Lancet Diabetes Endocrinol. 2020 07; 8(7):553-555.
-
Santos-Gallego CG, Garcia-Ropero A, Mancini D, Pinney SP, Contreras JP, Fergus I, Abascal V, Moreno P, Atallah-Lajam F, Tamler R, Lala A, Sanz J, Fuster V, Badimon JJ. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity? Cardiovasc Drugs Ther. 2019 02; 33(1):87-95.
-
Wang CZ, Wan JY, Zhang CF, Lu F, Chen L, Yuan CS. Deglycosylation of wogonoside enhances its anticancer potential. J Cancer Res Ther. 2018 Sep; 14(Supplement):S594-S599.
-
Yao D, Zhang L, Huang J, Sun C, Zhang Y, Gu X, Wang CZ, Li F, Chen L, Yuan CS. A surface magnetic imprinted polymers as artificial receptors for selective and efficient capturing of new neuronal nitric oxide synthase-post synaptic density protein-95 uncouplers. J Pharm Biomed Anal. 2018 May 30; 154:180-190.
-
Plutzky J, Bakris G. Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page. Circulation. 2018 01 09; 137(2):130-133.
-
Deng JH, Lu TB, Sun CC, Chen JM. Dapagliflozin-citric acid cocrystal showing better solid state properties than dapagliflozin. Eur J Pharm Sci. 2017 Jun 15; 104:255-261.
-
Majewski C, Bakris GL. Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes Care. 2015 Mar; 38(3):429-30.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|